{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T05:24:57.780446+00:00","company":{"ticker":"EXEL","cik":939767,"company_name":"EXELIXIS, INC."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"4ab92985997e5c8190616372c11c5a911501cc68","cik":939767,"ticker":"EXEL","company_name":"EXELIXIS, INC.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"$0.79 per share, diluted","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$210.5 million","period_text":"first quarter of 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":"$610.8 million"},"claim":"EXELIXIS, INC. reported first quarter of 2026 results: revenue $610.8 million, net income $210.5 million, EPS $0.79 per share, diluted.","evidence_excerpt":"& Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 - - Announced Additional Stock Repurchase Program","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0000939767-26-000058","anchor_url":"https://secwatch.observer/filing/0000939767-26-000058#claim-4ab92985997e5c8190616372c11c5a911501cc68","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/0000939767-26-000058-index.htm"},{"fact_type":"earnings_release","fact_key":"ffcd5ccec8ed53c279076ba970d24427822834f6","cik":939767,"ticker":"EXEL","company_name":"EXELIXIS, INC.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"eps_text":"$0.12","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"First Quarter 2024","report_date":"2024-04-30","result_type":"reported_results","revenue_text":"$425 million"},"claim":"EXELIXIS, INC. reported First Quarter 2024 results: revenue $425 million, EPS $0.12.","evidence_excerpt":"Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million - - Restructuring Expenses of $32.8 million Recorded - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.17 -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000939767-24-000054","anchor_url":"https://secwatch.observer/filing/0000939767-24-000054#claim-ffcd5ccec8ed53c279076ba970d24427822834f6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000054/0000939767-24-000054-index.htm"}]}